| 2026-08-21 | Press release | Kairos Pharma Announces 1-for-7 Reverse Stock Split |
| 2026-07-22 | Press release | Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer |
| 2026-07-15 | Press release | Download(opens in new window) |
| 2026-07-15 | Press release | Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients |
| 2026-06-29 | Press release | Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings |
| 2026-06-29 | Proxy statement | PRE 14A dated 05/11/2026 in pdf format download(opens in new window) |
| 2026-06-04 | Press release | Download(opens in new window) |
| 2026-05-26 | Press release | DEFA14A dated 05/26/2026 in pdf format download(opens in new window) |
| 2026-05-22 | Press release | DEF 14A dated 05/22/2026 in pdf format download(opens in new window) |
| 2026-05-15 | Presentation | Download Investor Presentation (opens in new window) |
| 2026-05-14 | Press release | Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award |
| 2026-05-14 | Presentation | Catalyst-Rich Second Half for Pipeline; 1Q26 results
Opens in a new window |
| 2026-05-08 | Press release | Download(opens in new window) |
| 2026-04-15 | Press release | Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation |
| 2026-04-02 | Earnings deck | Strategic Acquisition Bridges the Gap to High-Value Oncology Combination Therapy; 2025 Results
Opens in a new window |
| 2026-03-02 | Press release | Download(opens in new window) |
| 2026-03-02 | Press release | Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From Orbi |
| 2026-02-26 | Press release | Download(opens in new window) |
| 2026-02-26 | Press release | Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from |
| 2026-01-20 | Press release | Download(opens in new window) |
| 2025-12-17 | Press release | Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer |
| 2025-11-04 | Press release | Kairos Pharma Provides Shareholder Update |
| 2025-11-04 | Fact sheet | Kairos Shareholder Update: Advancing ENV105 and
Expanding Oncology Portfolio
Opens in a new window |
| 2025-11-04 | Press release | Kairos Pharma Provides Shareholder Update |
| 2025-10-20 | Press release | Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists ( |
| 2025-10-20 | Fact sheet | Kairos Pharma Highlights Interim Phase 2 Data for
ENV-105 in Advanced Prostate Cancer
Opens in a new window |
| 2025-10-07 | Press release | Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 |
| 2025-10-07 | Fact sheet | Kairos PharmaOpens in a new
window |
| 2025-09-19 | Fact sheet | Promising Interim P2 Data for ENV105Opens in a
new window |
| 2025-09-18 | Press release | Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with M |
| 2025-06-04 | Fact sheet | ASCO Data on KROS101 a Small Molecule GITR Ligand
AgonistOpens in a new window |
| 2025-04-16 | Presentation | KAPA: 2024 Results; Oncology Pipeline Poised for
Multiple Readouts;
Initial Phase 2 ENV-105 mCRPC Data Expected 1H25Opens in a new
window |
| 2025-03-20 | Fact sheet | Kairos Highlights Breakthrough in Overcoming EGFR
Resistance in Lung
CancerOpens in a new window |
| 2025-02-26 | Fact sheet | Evidence for KROS 101 and KROS 401 in Melanoma and
GlioblastomaOpens in a new window |
| 2025-02-18 | Fact sheet | Department of Defense Funds Kairos Pharma’s ENV205
Research,
Strengthening Drug Development PipelineOpens in a new window |
| 2024-11-14 | Fact sheet | Prostate Cancer Trial Expands Beyond CedarsOpens
in a new window |
| Press release | Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders |